CClinicalTrials.gg
Status unknownNCT03287388RELAX-2Updated Apr 2, 2019

MRI Measurement of the Effects of Deep Neuromuscular Blockade on the Abdominal Working Space During Laparoscopy

An interventional study of No Rocuronium and Rocuronium (moderate NMB) in Neuromuscular Block and Surgery, sponsored by Radboud University Medical Center. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-02.

Sponsored by Radboud University Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

During laparoscopy, a surgical working space is obtained by creation of a pneumoperitoneum. Optimal surgical conditions are essential to ensure the patient's safety. A meta-analysis on studies comparing the influence of deep and moderate neuromuscular blockade (NMB) on the quality of the surgical space conditions during laparoscopy (1), showed that compared to moderate NMB, deep neuromuscular blockade improves the surgical space conditions, assessed by the Leiden-Surgical Rating scale, as reported by Martini and colleagues (2).

In this prospective cohort study, we will assess the influence of deep neuromuscular blockade on the surgical space, measured by magnetic resonance imaging (MRI) in patients scheduled for laparoscopic donor nephrectomy

Read the detailed description

Objective: To establish the influence of deep neuromuscular blockade (NMB) on the abdominal working space during laparoscopy.

Study design: A single center prospective cohort study

Study population: 10 adult patients (18 years or older), equally distributed by gender, scheduled for laparoscopic donor nephrectomy

Study procedures:

Induction of general anesthesia followed by intubation and creation of a pneumoperitoneum (12 mmHg).

Each patient will have a MRI scan during 3 stages:

Phase 1: No neuromuscular blockade (TOF ratio 1) Phase 2: moderate neuromuscular blockade(TOF 1-3). Phase 3: deep neuromuscular blockade (PTC 0-1)

Primary outcome:

The abdominal space measured by MRI: Skin - sacral promontory distance

Secondary outcome:

3D volume measurement of the abdominal cavity by MRI.

02

Conditions studied

  • Neuromuscular Block
  • Surgery

Keywords

  • Laparoscopic surgery
  • Abdominal working space
  • Moderate neuromuscular blockade
  • Deep neuromuscular blockade
  • MRI measurement
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • scheduled for laparoscopic donor nephrectomy
  • obtained informed consent

Exclusion criteria

Exclusion Criteria:

  • Unable to provide informed consent
  • known or suspect allergy to mivacurium, rocuronium or sugammadex
  • neuromuscular disease
  • indication for rapid sequence induction
  • Being unable to undergo MRI due to any reason (e.g. non MRI-compatible implants, epilepsy)
  • BMI>30 kg/m2
  • American Society of Anesthesiologists (ASA) classification >2
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    No Rocuronium

    Phase 1: no neuromuscular blockade

    Procedure: No Rocuronium

  • Experimental
    Rocuronium (moderate NMB)

    Phase 2: moderate neuromuscular blockade (TOF 1-3)

    Drug: Rocuronium (moderate NMB)

  • Experimental
    Rocuronium (deep NMB)

    Phase 3: deep neuromuscular blockade (PTC 0-1)

    Drug: Rocuronium (deep NMB)

Interventions

  • ProcedureNo Rocuronium

    Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.

    Also known as: No neuromuscular blockade

  • DrugRocuronium (moderate NMB)

    Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.

    Also known as: Moderate neuromuscular blockade (Rocuronium)

  • DrugRocuronium (deep NMB)

    Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.

    Also known as: Deep neuromuscular blockade (Rocuronium)

05

What researchers measure

Primary outcomes

  1. Abdominal working space

    Skin-sacral promontory distance, measured by MRI

    Time frame: 3 times (phase 1 (no neuromuscular blockade, phase 2 moderate neuromuscular blockade, phase 3 deep neuromuscular blockade. From start of surgery until third scan, total duration of 30 minutes

Secondary outcomes

  1. Abdominal volume

    3D volume abdominal cavity, measured by MRI

    Time frame: 3 times (phase 1 no neuromuscular blockade, phase 2 moderate neuromuscular blockade, phase 3 deep neuromuscular blockade. From start of surgery until third scan, total duration of 30 minutes

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Bruintjes MH, van Helden EV, Braat AE, Dahan A, Scheffer GJ, van Laarhoven CJ, Warle MC. Deep neuromuscular block to optimize surgical space conditions during laparoscopic surgery: a systematic review and meta-analysis. Br J Anaesth. 2017 Jun 1;118(6):834-842. doi: 10.1093/bja/aex116. PubMed 28575335 ↗
  • Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. Br J Anaesth. 2014 Mar;112(3):498-505. doi: 10.1093/bja/aet377. Epub 2013 Nov 15. PubMed 24240315 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT03287388
Lead sponsor
Radboud University Medical Center
Collaborators
Merck Sharp & Dohme LLC
Responsible party
Sponsor
First posted
Sep 19, 2017
Start date
May 2019 (estimated)
Primary completion
Nov 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Apr 2, 2019

Study contacts

Moira HD Bruintjes, Msc.
Contact
Moira.Bruintjes@radboudumc.nl
(+)31-24-3617612
Piet Krijtenburg, Drs.
Contact
Piet.Krijtenburg@radboudumc.nl
(+)31-24-3619032
Michiel C Warlé, Dr.
principal investigator · Radboud University Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion